Impact of a decision aid about stratified ovarian cancer risk-management on women's knowledge and intentions: a randomised online experimental survey study. by Meisel, SF et al.
RESEARCH ARTICLE Open Access
Impact of a decision aid about stratified
ovarian cancer risk-management on
women’s knowledge and intentions: a
randomised online experimental survey
study
Susanne F. Meisel1,2, Maddie Freeman1, Jo Waller1, Lindsay Fraser3, Sue Gessler3, Ian Jacobs4, Jatinderpal Kalsi3,
Ranjit Manchanda3, Belinda Rahman3, Lucy Side6, Jane Wardle1ˆ, Anne Lanceley3, Saskia C. Sanderson1,5*
and on behalf of the PROMISE team
Abstract
Background: Risk stratification using genetic and other types of personal information could improve current best
available approaches to ovarian cancer risk reduction, improving identification of women at increased risk of
ovarian cancer and reducing unnecessary interventions for women at lower risk. Amounts of information given to
women may influence key informed decision-related outcomes, e.g. knowledge. The primary aim of this study was
to compare informed decision-related outcomes between women given one of two versions (gist vs. extended) of
a decision aid about stratified ovarian cancer risk-management.
Methods: This was an experimental survey study comparing the effects of brief (gist) information with lengthier,
more detailed (extended) information on cognitions relevant to informed decision-making about participating in
risk-stratified ovarian cancer screening. Women with no personal history of ovarian cancer were recruited through
an online survey company and randomised to view the gist (n = 512) or extended (n = 519) version of a website-
based decision aid and completed an online survey. Primary outcomes were knowledge and intentions. Secondary
outcomes included attitudes (values) and decisional conflict.
Results: There were no significant differences between the gist and extended conditions in knowledge about
ovarian cancer (time*group interaction: F = 0.20, p = 0.66) or intention to participate in ovarian cancer screening
based on genetic risk assessment (t(1029) = 0.43, p = 0.67). There were also no between-groups differences in
secondary outcomes. In the sample overall (n = 1031), knowledge about ovarian cancer increased from before to
after exposure to the decision aid (from 5.71 to 6.77 out of a possible 10: t = 19.04, p < 0.001), and 74% of
participants said that they would participate in ovarian cancer screening based on genetic risk assessment.
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Conclusions: No differences in knowledge or intentions were found between women who viewed the gist version
and women who viewed the extended version of a decision aid about risk-stratified ovarian cancer screening.
Knowledge increased for women in both decision aid groups. Further research is needed to determine the ideal
volume and type of content for decision aids about stratified ovarian cancer risk-management.
Trial registrations: This study was registered with the ISRCTN registry; registration number: ISRCTN48627877.
Background
Ovarian cancer remains the leading cause of gynaeco-
logical cancer death in the UK, with approximately 11
women dying from the disease each day [1]. A lack of
disease-specific symptoms during early disease makes
diagnosis challenging and most women are diagnosed
at an advanced stage when the cancer has already
spread beyond the ovaries. Diagnosis at an earlier
stage (e.g. Stage 1) carries a significantly better prog-
nosis with more than 90% of patients alive at 5 years
post-diagnosis.
This observation has prompted a significant global
effort to develop strategies that can lead to early de-
tection of ovarian cancer. There is some evidence
suggesting that a screening strategy involving serial
sampling (annual or 4-monthly) of serum CA125
levels interpreted by the Risk of Ovarian Cancer
Algorithm (ROCA), and incorporating selective
transvaginal ultrasound scanning (TVS) may improve
risk management of women in both the general
population and those at increased risk [2–4]; however,
the potential impact on disease-specific mortality is
not yet known. The largest of the randomised
controlled ovarian cancer screening trials, United
Kingdom Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS), is continuing to follow its cohort to deter-
mine the long term impact of annual screening on ovarian
cancer death rates [5]. At present screening for ovarian
cancer using existing methodologies is not advocated [6].
The recent advances in genomic and other -omic tech-
nologies present an opportunity to develop more perso-
nalised approaches to cancer screening where genetic
predisposition, epidemiological and lifestyle factors may
be combined to assess individual cancer risk. Screening
efficiency may be improved by focussing on high-risk in-
dividuals and tailoring screening and other preventative
and early detection activities to their needs while mini-
mising harms to individuals at lower disease risk.
General population surveys and surveys of specific pa-
tient subgroups such as women at high risk of cancer
suggest that public interest in stratified approaches to
cancer risk-management is high [7–10].
As in almost all areas of medical care, patients must
be helped to make decisions that reflect their autonomy
and that are adequately informed [11, 12]. In addition to
the usual anticipated harms of screening (including
false-positive results, surgical complications, short-term
anxiety, and overdiagnosis), identification of increased
genetic risk may also prompt life-changing decisions to
be made (e.g. prophylactic surgery) and may necessitate
testing of family members with far reaching conse-
quences. There is also the added complication of how to
manage genetic variants of uncertain clinical signifi-
cance. Patients will need to be helped to make informed
decisions that take these complex potential benefits and
risks into account and that are ‘based on relevant know-
ledge, consistent with the decision-maker’s values and be-
haviourally implemented’ [13].
Decision aids are evidence-based tools that outline
different healthcare options and consequences in an
organised fashion with the purpose of helping patients
make informed decisions [14]. As well as conveying im-
portant information, decision aids also include questions
aimed at clarifying personal values and preferences to re-
mind the decision-maker to take these into account [15].
We are engaged in PROMISE (‘Predicting Risk of
Ovarian Malignancies, Improved Screening and Early
Detection’), a large collaborative international research
programme that aims to develop and validate models for
ovarian cancer risk stratification, early detection and
diagnosis, incorporating clinical, epidemiological, prote-
omic and genetic data (https://www.eveappeal.org.uk/
about/research/promise, accessed 28 March 2017). In
PROMISE, we are also conducting a pilot study to inves-
tigate the feasibility of applying a stratified approach to
managing ovarian cancer risk. To aid potential recruits
to make a decision about participation in the pilot study
applying the risk stratification approach developed in
PROMISE, we have been working to develop a decision
aid. As a first step in this process, we examined the
impact of two beta versions of a decision aid that
focused on the use of genetic testing in ovarian cancer
risk stratification. We measured outcomes related to
informed decision-making among people in the general
population, and compared two levels of detail of the in-
formation presented.
We are not aware of any previous research addressing
decisions about stratified cancer risk-management in a
general population sample. Nor are we aware of any
studies that have systematically evaluated how the volume
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of information contained in a decision aid affects
cognitions relevant to informed decision-making for
ovarian cancer risk-management. Therefore, we tested
the impact of providing two levels of information
(gist vs. extended) on cognitions relevant to informed
decision-making about personalized (genetic) stratified
ovarian cancer risk-management in a web-based
experimental study.
Study objectives and hypotheses
The primary research objective was to describe and com-
pare key informed decision-related outcomes between two
versions of a decision aid about personalized risk-stratified
ovarian cancer screening (gist vs. extended). The primary
outcomes were (1) knowledge about ovarian cancer and
the PROMISE study and (2) intention to participate in
personalized risk-stratified ovarian cancer screening in
PROMISE; secondary outcomes included (3) attitudes
(values) towards taking part in PROMISE. Based on cogni-
tive load theory [16, 17], we hypothesised that participants
receiving the shorter ‘gist’ information would have higher
knowledge about key components of risk-stratified ovarian
cancer screening in the PROMISE study than those
receiving the longer ‘extended’ information. This is
because fewer demands would be placed on working
memory in the ‘gist’ condition and so content-related
information would be processed more effectively. The sec-
ondary research objectives were to describe and compare
attitudes (values) and other decision-related outcomes
(decisional conflict and decision satisfaction) between
the gist and extended versions of the information.
Methods
Study design
This was a single-blind, two-arm, individually-randomised,
controlled experimental survey study comparing the effects
of brief (gist-based) information with lengthier, more detailed
(extended) information on cognitions relevant to informed
choice about participation in personalized risk-stratified ovar-
ian cancer screening (i.e. intentions, knowledge, attitudes).
Given that an increasing amount of health information is
accessed online, the study was web-based.
Decision aid
We created two versions of an online decision aid for
the purpose of this study. The decision aid content was
informed by: interviews about knowledge and attitudes
towards the proposed PROMISE programme among
members of the public; interviews about knowledge and
attitudes towards the proposed PROMISE programme
among women at high risk of ovarian cancer [10]; a
systematic review of the literature; and existing clinical
information designed for women at high risk of ovarian can-
cer. The decision aids outlined information about ovarian
cancer risk, genetic testing, and the risk-stratification
programme (PROMISE), and contained a values clarification
exercise which aimed to help participants make a hypothet-
ical decision about PROMISE that was in line with their
personal values. The International Patient Decision Aid Stan-
dards Collaboration (IPDAS) criteria were followed and all
content was written for grade 8 reading level or below, as
recommended by IPDAS. One version of the decision aid
contained gist information and the other contained extended
information (see below). With the exception of amount of
content detail (gist vs extended), all other components of the
online decision aid (layout, overarching themes, and values
clarification exercise) were standardised and the same in
both versions. The content of both decision aids can be
found in the Additional file 1.
Gist information
The ‘gist’ version of the decision aid was 5 pages long.
Participants randomized to the gist version of the deci-
sion aid were invited to browse it at their leisure. They
could access each component of the website in the order
they preferred. At any point they could choose to access
the values clarification exercise (by clicking on a ‘Ready
to decide?’ button).
Extended information
The ‘extended’ version of the decision aid was 8 pages
long, and was based on information given to patients at-
tending clinical genetics services (designated as the
‘usual care’ arm of the trial). Participants randomized to
the ‘extended’ version of the decision aid were also in-
vited to browse it at their leisure. Identical to the inter-
vention group, they could also access each component
of the website in the order they preferred, and they




We included women aged 18–74 years. Quotas were set
for education to broadly reflect those of the UK general
population. Participants were recruited through an on-
line survey company (Survey Sampling International;
SSI) who were blind to the study hypothesis. SSI curates
a panel of members of the UK general population who
are willing to participate in online surveys in exchange
for minor rewards (e.g. air miles), with the aim of redu-
cing the possibility of drop-out and subsequent selection
bias. Panel members invited to participate were asked
whether they had ever been diagnosed with ovarian
cancer in order to assess eligibility to complete the full
survey. We excluded women with a personal history of
ovarian cancer (but not breast cancer) because they were
already able to access specific risk management options
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according to NICE (National Institute for Health and
Care Excellence) guidelines [18]. After discussion with
the wider research team, we decided not to exclude
participants with a family history of ovarian cancer be-
cause it would be unlikely that they would be excluded if
a stratified approach to ovarian cancer risk-management
was introduced as a novel screening programme.
Interested and eligible participants indicated their con-
sent to take part in the study by entering and completing
the baseline survey. It was made clear that data would
be stored according to data protection regulations and
that participants could withdraw from the study at any
time without any personal consequences. It was made
clear that the decision to participate in PROMISE was
hypothetical only (i.e. they would not actually be able to
receive information about their personal risk of develop-
ing ovarian cancer).
Study duration
Participants received the follow-up questionnaire via
an email link 1–2 h after they accessed the website.
Recruitment into the study stopped once target numbers
were achieved. Data were collected in August 2015.
Randomisation
Consenting participants were randomised to the gist in-
formation group or the extended information group
using an in-built randomisation algorithm used by SSI
(group allocation ratio 1:1). Participants were blinded to
their group allocation and were simply told they would
be viewing one version of a website about an ovarian
cancer screening study. All data, including randomisa-
tion, were recorded, minimising the risk of experimenter
bias. Recording all data online also minimised the risk of
missing data or inadvertent manipulation.
Sample size and assumptions
A power calculation using GPower (version 3.1) showed
that a sample of 990 women would give 80% power to
detect a between-group difference in informed decision-
making outcomes (medium effect size) at alpha = 0.05.
Ethics
This study received ethical approval from UCL Research
Ethics Committee.
Measures
Demographic and personal information
Demographic information collected included age, ethni-
city and education. Personal information included blood
relatives diagnosed with ovarian cancer or breast cancer,
past participation in any of the NHS cancer screening
programmes (cervical, breast, colorectal), and perceived
risk of ovarian [breast] cancer in comparison with other
women of the same age (‘compared with other women
your age would you say your risk of ovarian [breast] can-
cer is’…‘much lower than others’, ‘lower than others’, ‘same
as others’, ‘higher than others’, ‘much higher than others’).
This was based on a measure of perceived health risks
[19]. Worry about ovarian cancer and worry about
breast cancer were assessed with items used in previous
studies: ‘I worry about getting ovarian [breast] cancer’
(‘never’, ‘rarely’, ‘sometimes’, ‘often’, ‘most of the time’). This
measure was adapted from the Health Information
National Trends Survey [20].
Genetic literacy was assessed with six statements used
in previous research [21–24]: 1) Genes are inside cells
(true); 2) Genes are made up of DNA (true); 3) Most
genetic disorders are caused by a single gene (not true);
4) If a person has a faulty gene that has been linked with
a disorder, they will always get the disorder (not true);
5) On average, a person has half their genes in common
with their biological siblings (true); 6) A mother and
daughter who look alike have more genes in common
than a mother and a daughter who do not look alike
(not true). Response options for each question were
‘true’, ‘not true’, and ‘not sure’.
Knowledge
Knowledge about ovarian cancer was assessed using four
statements specifically developed for this study (bold
font indicates response options coded as ‘correct’ and
consistent with the information provided in the decision
aid): 1) The average risk of a woman developing ovarian
cancer in her lifetime is… (1 in 8; 1 in 50; 1 in 1000); 2)
Ovarian cancer mainly affects older women (‘true’; ‘not
true’; ‘not sure’); 3) Ovarian cancer can easily be found
early with an ultrasound scan (‘true’; ‘not true’; ‘not
sure’); 4) There are some factors that increase the risk of
developing ovarian cancer: being overweight; being
over 50 years old; smoking; family history; taking the
pill; having children; breastfeeding; being inactive; using
talcum powder; having IVF treatment (Please tick all
that you think apply). Participants also scored up to
three points if they correctly identified that taking the
pill, having children and breastfeeding were not risk
factors for ovarian cancer, as these have clearly been
shown to be protective factors. This gave a total possible
score of 10. The questions were adapted from the ovar-
ian cancer awareness measure toolkit [25].
Knowledge about PROMISE was assessed using six
statements: 1) Genetic testing for ovarian cancer in-
volves giving a blood sample (true); 2) PROMISE uses
genetic information to estimate the risk of developing
ovarian cancer (true); 3) Learning about personal risk of
ovarian cancer may affect other family members (true);
4) Most women who take part in PROMISE will learn
that they are at high risk of ovarian cancer (not true); 5)
Meisel et al. BMC Public Health  (2017) 17:882 Page 4 of 13
Women at high risk can’t do anything to reduce their
chance of getting ovarian cancer (not true); 6) Women
who take part in PROMISE will get some information
about their risk of breast cancer (true). Response op-
tions for all statements were ‘true’; ‘not true’; ‘not sure’.
Attitudes (values) towards taking part in PROMISE
Attitudes towards taking part in PROMISE were mea-
sured using a validated scale by Hersch and colleagues
[26]. The scale consists of six items, each on a five-point
response scale: Each item was preceded by the state-
ment: ‘For me, taking part in ovarian cancer screening
based on genetic risk assessment would be…’: A bad
thing – Not a bad thing; Beneficial – Not beneficial;
Harmful – Not harmful; A good thing – Not a good
thing; Worthwhile – Not worthwhile; Important –
Unimportant. Responses were summed and a mean atti-
tude score was created ranging from 1 to 5.
Intention to participate in the PROMISE study
Intention to take part in risk-stratified ovarian cancer
screening based on genetic risk was adapted from a
question by Power and colleagues [27]: ‘If you were in-
vited to take part in ovarian cancer screening based on
genetic risk assessment would you take up the offer?’,
with response options being ‘yes, definitely’; ‘yes, prob-
ably’; ‘probably not’; ‘definitely not’ (where 1 = definitely
not, 4 = yes definitely).
Decisional conflict and anticipated decisional regret
Decision-related outcomes were assessed using six
items adapted from the decisional conflict scale [28]:
1) I would be satisfied with my decision of whether
or not to take part in PROMISE, 2) I feel I would
make an informed choice about taking part in
PROMISE, 3) I would expect to stick with my deci-
sion of whether or not to take part in PROMISE, 4) I
know the risks of taking part in PROMISE, 5) I feel
unsure about what I would choose – taking part in
PROMISE or not taking part, 6) The decision of
whether or not to take part in PROMISE would be
easy for me. Anticipated decisional regret was
assessed using two items based on Abraham and
Sheeran’s [29] measure of anticipated regret: 1) If I
did not take part in PROMISE, I would feel regret; 2)
If I did not take part in PROMISE, I would later wish
I had. All responses were recorded on four-point
scales ranging from strongly disagree to strongly
agree. The decisional conflict items were reverse
coded, so that a high score indicated high decisional
conflict. A principal components analysis with vari-
max rotation was run and this confirmed the two fac-
tor structure (see Additional file 2: Table S1).
Website usage
Website usage was assessed at follow-up using three
questions: ‘I read all the information on the website’
(‘very thoroughly’; ‘quite thoroughly’; ‘briefly’; ‘just the
parts I felt were relevant’); ‘There was enough informa-
tion on the website to make a decision about whether or
not to take part in PROMISE (‘strongly agree’; ‘agree’;
‘disagree’; ‘strongly disagree’), and ‘I would have preferred
to speak to a health professional before making a deci-
sion about whether or not to take part in PROMISE
(‘strongly agree’; ‘agree’; ‘disagree’; ‘strongly disagree’).
Demographic and personal information, worry about
breast and ovarian cancer, genetic literacy and health lit-
eracy were assessed before the decision aid intervention.
Perceived risk of ovarian cancer and knowledge of ovar-
ian cancer were measured pre and post exposure to the
decision aid. Knowledge about PROMISE, attitudes, in-
tentions, decisional conflict, anticipated decisional regret
and website usage were assessed after the decision aid
intervention only (see Table 1).
Statistical analyses
Socio-demographic and outcome variables were described
using frequencies, means and standard deviations. Out-
come variables were compared cross-sectionally between
the ‘gist’ and ‘extended’ information decision aid condi-
tions using a series of independent samples t-tests.
Change over time in knowledge about ovarian cancer
from before to after the decision aid was examined and
compared between-groups using a repeated measures
ANOVA with group (gist vs. extended) as an independent
variable, and the time*group interaction reported. P-values
Table 1 Constructs measured and time of assessment








Worry about breast and ovarian
cancer
✓ ✗
Genetic literacy ✓ ✗
Health literacy ✓ ✗
Perceived risk of ovarian cancer ✓ ✓
Knowledge about ovarian cancer ✓ ✓
Knowledge about PROMISE ✗ ✓
Attitudes towards taking part in
PROMISE
✗ ✓
Intention to take part in PROMISE ✗ ✓
Decisional conflict ✗ ✓
Anticipated decisional regret ✗ ✓
Website usage ✗ ✓
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of less than 0.05 were considered significant. All analyses
were conducted with SPSS version 23.
Results
Sample characteristics
Overall, 1031 women participated in the study. There
were 512 participants in the ‘gist’ decision aid group and
519 in the ‘extended’ group. Women were well distrib-
uted across the age groups, and ranged from 18 years
upwards, with 7% aged 65 and over. The majority of par-
ticipants were White (79.6%), spoke English as their first
language (90.9%), and 26% were educated to Degree
level. None had had a previous diagnosis of ovarian can-
cer. Twenty-five percent of participants had a family his-
tory of breast cancer, and 8.1% had a family history of
ovarian cancer. Two thirds (68.8%) of participants per-
ceived their risk of getting ovarian cancer to be the same
as other women of their age. Forty-four percent of
women reported worrying ‘sometimes’ about breast can-
cer, and 33.8% reported worrying ‘sometimes’ about
ovarian cancer. The full socio-demographic characteris-
tics of the sample and each group are illustrated in
Table 2. In addition, (Additional file 2: Table S2) shows
participants’ responses to the individual items for genetic
literacy, and shows that participants’ mean genetic liter-
acy score was 3.47 (where 0 = low and 6 = high).
Knowledge
Knowledge about ovarian cancer increased from pre- to
post-intervention in the sample overall (from 5.71 to
6.77, out of a possible 10: F = 362.25, p < 0.001). There
was no significant difference between the gist and ex-
tended conditions (time*group interaction: F = 0.20, p =
0.66). The mean score for knowledge about PROMISE
was 3.97 out of 6 after the decision aid; mean scores
were not significantly different between the gist and ex-
tended conditions (4.02 vs. 3.92 respectively: t(1029) =
0.87, p = 0.39) (see Table 3). In addition, (Additional file 2:
Table S3) shows participants’ knowledge in the sample
overall.
Attitudes (values) towards participating in PROMISE
The mean score for attitudes towards PROMISE was
3.91 (where 1 = negative attitude, 5 = positive attitude);
mean scores were not significantly different between the
gist and extended conditions (3.92 vs. 3.89 respectively,
t(1029) = 0.60, p = 0.55) (see Table 3).
Intention to participate in the PROMISE study
In the sample overall, 74% of participants said that they
‘probably’ or ‘definitely’ would participate in ovarian can-
cer screening based on genetic risk assessment (the
PROMISE study); there was no difference between the







N (%) N (%) N (%)
Age
18–29 199 (19.3) 109 (21.3) 90 (17.3)
30–39 222 (21.5) 104 (20.3) 118 (22.7)
40–49 228 (22.1) 115 (22.5) 113 (21.8)
50–59 210 (20.4) 99 (19.3) 111 (21.4)
60+ 172 (16.7) 85 (16.6) 87 (16.8)
Ethnicity
White 821 (79.6) 402 (78.5) 419 (80.7)
Asian 95 (9.2) 52 (10.1) 43 (8.3)
Black 68 (6.6) 31 (6.0) 37 (7.1)
Mixed 34 (3.3) 20 (4.0) 14 (2.7)
Other 8 (0.8) 6 (1.2) 2 (0.4)
First language
English 937 (90.9) 460 (89.8) 477 (91.9)
Other 93 (9.0) 52 (10.2) 41 (7.9)
Education
Degree or equivalent 268 (26.0) 130 (25.4) 138 (26.6)
Higher education 112 (10.9) 55 (10.7) 57 (11.0)
A Level or equivalent 235 (22.8) 112 (21.9) 123 (23.7)
GCSEs grades A*-C or
equivalent
256 (24.8) 140 (27.3) 116 (22.4)
Other qualifications 83 (8.1) 42 (8.2) 41 (7.9)
No formal
qualifications
73 (7.1) 32 (6.3) 41 (7.9)
Family history of breast
cancer (yes)
258 (25.0) 125 (24.4) 133 (25.6)
Family history of ovarian
cancer (yes)
84 (8.1) 47 (9.2) 37 (7.1)
Comparative risk of ovarian cancer
Much lower than
others
79 (7.7) 37 (7.2) 42 (8.1)
Lower than others 147 (14.3) 81 (15.8) 66 (12.7)
Same as others 709 (68.8) 350 (68.4) 359 (69.2)
Higher than others 85 (8.2) 39 (7.6) 46 (8.9)
Much higher than
others
11 (1.1) 5 (1.0) 6 (1.2)
Worry about breast cancer
Never 102 (9.9) 43 (8.4) 59 (11.4)
Rarely 270 (26.2) 139 (27.1) 131 (25.2)
Sometimes 457 (44.3) 235 (45.9) 222 (42.8)
Often 152 (14.7) 70 (13.7) 82 (15.8)
Always 50 (4.8) 25 (4.9) 25 (4.8)
Worry about ovarian cancer
Never 256 (24.8) 115 (22.5) 141 (27.2)
Rarely 354 (34.3) 184 (35.9) 170 (32.8)
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gist and extended conditions (t(1029) = 0.43, p = 0.67)
(see Table 3).
Decisional conflict and anticipated decision regret
Decisional conflict: Overall, the majority (94%) of partici-
pants agreed or strongly agreed that they would feel that
they would be making an informed choice about taking
part in PROMISE, and three quarters (77%) reported
that they knew the risks of taking part in PROMISE.
However, over half (54%) also felt unsure about what
they would choose, and only two thirds (67%) felt that
the decision about whether or not to take part in
PROMISE would be easy for them. The mean score for
decisional conflict was 2.09 (SD = 0.32) (where 1 = low
decisional conflict, and 4 = high decisional conflict).
Mean scores did not differ between the gist and ex-
tended information decision aid groups (t(1029) = 0.20,
p = 0.84).
Anticipated decisional regret: In the sample overall,
49% of participants agreed or strongly agreed that if
they did not take part in PROMISE they would feel
regret, and similarly 55% agreed or strongly agreed
that if they did not take part, they would later wish
they had. The mean anticipated decisional regret
score was 2.56 (SD = 0.66), on a scale where 1 = low
anticipated regret, and 4 = high anticipated regret.
Mean scores did not differ between the gist and ex-
tended information groups (t(1029) = 0.02, p = 0.98)
(see Table 4).
Website usage
There was no significant difference between the gist and
extended groups in the amount of information on the
website-based decision aid that participants reported
reading (t(1029) = −0.15, p = 0.88). There was also no
significant difference between the two groups in the pro-
portions of participants who thought the website
contained sufficient information to make a decision
about whether or not to take part in PROMISE (t(1029)
= −1.34, p = 0.18) (see Table 5).
Discussion
This study examined the effects of a web-based deci-
sion aid on key components of informed decision-
making about risk-stratified ovarian cancer manage-
ment, and compared the effects between a gist and
an extended version of the decision aid. We found
that knowledge about ovarian cancer improved signifi-
cantly overall, indicating that the decision aid was
successful in increasing knowledge; an essential
component of informed choice. This finding is con-
sistent with a review which found that decision aids
increased patients’ knowledge about treatment or
screening options [30]. Although scores on most of
the ovarian cancer knowledge items were high after
participants had viewed the decision aid, two of the
items (‘Ovarian cancer mostly affects older women’
[True], and ‘Ovarian cancer can be found easily with
an ultrasound scan’ [Not true]) were coded as being
answered correctly by fewer than half the participants
(44.3% and 26.3% respectively). This may reflect am-
biguity in the question wording, and/or that the deci-
sion aids did not express this information sufficiently
clearly. Future versions of the information presented
to participants in the decision aid and the measures
used to assess understanding of that information will
need to make these facts and their measurement
clearer.
To our knowledge, this is the first study to assess
the impact of a gist versus extended version of a de-
cision aid about risk-stratified ovarian cancer screen-
ing on aspects of informed decision-making. Different
components of informed decision-making were mea-
sured, including knowledge, intentions and attitudes,
in an attempt to capture the multidimensional nature
of informed choice [13]. Moreover, individual item
scores were examined, rather than just their compos-
ites, to obtain a detailed understanding of partici-
pants’ knowledge and beliefs. The study sample was
large and diverse in terms of age and education.
Despite the lack of difference between the two deci-
sion aids on informed choice outcomes, it was en-
couraging to observe that more participants intended
to participate in PROMISE than not (74.2% vs.
25.8%). This suggests that a risk-stratified approach to
screening for ovarian cancer and other management
options might be considered acceptable to the major-
ity of women within the general public, and if it were
to be introduced, uptake could be high.
Our findings also suggest that providing participants in
the planned PROMISE feasibility study with a decision aid








N (%) N (%) N (%)
Sometimes 348 (33.8) 177 (34.6) 171 (32.9)
Often 53 (5.1) 22 (4.3) 31 (6.0)
Always 20 (1.9) 14 (2.7) 6 (1.2)
Previous participation in cancer screening tests
Cervical 774 (75.1) 377 (73.6) 397 (76.5)
Breast 400 (38.8) 193 (37.7) 207 (39.9)
Colorectal 162 (15.7) 79 (15.4) 83 (16.0)
None of above 214 (20.8) 114 (22.3) 100 (19.3)
Note. In cases where percentages do not add up to 100%, this represents
missing data
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may valuably help increase potential participants’ under-
standing of some key concepts, and that either a gist or
extended version could achieve this desired outcome.
There were no differences in knowledge about ovarian
cancer, knowledge about the PROMISE study or inten-
tions to participate in the PROMISE programme between
those who viewed the gist and those who viewed the
extended version of the decision aid. Neither were there
differences in attitudes towards PROMISE, anticipated
regret or decisional conflict between the two groups. The
absence of differences in components of informed
decision-making between the two groups suggests that the
amount of information provided in the decision aid had
little impact on people’s knowledge acquisition, attitudes
or intention. Contrary to the study hypotheses, we found
no evidence that participants in the gist group were able
to retain more information, nor that those in the extended
group experienced information overload. These findings
support previous research which found no difference in
colorectal cancer screening interest between participants
who received a brief decision aid with two screening op-
tions and those who were given a more detailed decision
aid containing five options [31].
An alternative explanation for the study’s results is
that the two versions of the decision aid were not
sufficiently different to elicit differences in informed
decision-making outcomes. The gist version was five
pages long, and the extended version was eight pages,
so perhaps this was not enough of a difference to
affect information-processing. In light of this it might
be worthwhile for future research comparing different
levels of information in decision aids to ensure that
gist versions are limited to one or two pages, to es-
tablish a sufficient difference between experimental
groups. Moreover, all participants were able to access
as much or as little information as they desired, albeit
within the confines of their version of the decision
aid. Detail about which pages each participant
accessed and for how long was not recorded, so it is
not known how much information each participant
actually read. It is therefore possible that the amount
of information read by participants in the two groups
did not differ.
It is also possible that the modality of the decision aid
(i.e. website) was not particularly well-suited to the type
of decision that was being made. Wilson and Wolf [17]
claim that the type of medium chosen for a decision aid
can affect cognitive load, which can impact upon in-
formed decision making outcomes. Although static
media, such as the decision aids used in the present
study, are appropriate for certain medical contexts, e.g.
when complex information must be repeatedly reviewed,
video is potentially more effective for single-event deci-
sions, e.g. deciding whether or not to take part in the
PROMISE programme.
Decision aids are an effective tool to increase pa-
tients’ knowledge of their options when faced with a
healthcare decision, so are likely to be valuable tools
to help people make informed decisions. It is there-
fore potentially important that healthcare profes-
sionals consider providing patients with decision aids,
and that such decision aids are available to them.
This will be particularly important if stratified ovarian
cancer risk-management becomes implemented in
clinical practice, because it is a novel approach to
screening and thus most patients’ knowledge of this
concept will be low. Decision aids may be pivotal in
improving knowledge levels and helping women to
clarify their values in order to make informed
decisions. Future research could explore the effect of
providing women with decision aids about stratified
ovarian cancer risk-management that are more differ-
ent to each other in terms of the amount of informa-
tion that is provided. The format of decision aid
could also be manipulated, for example by using mo-
bile apps and printed materials as well as websites, to
Table 5 Website usage
Item Response options Total sample (n = 1031)
N (%)
Gist group (n = 512)
N (%)
Extended group (n = 519)
N (%)
I read all the information on the website Very thoroughly
Quite thoroughly
Briefly













Mean (range = 1–4) (SD) 2.25 (0.90) 2.24 (0.87) 2.25 (0.92)a
Imagine you were invited to take part
in the study described on the website
when you answer the following questions.
There was enough information on the
website to make a decision whether or

















Mean (range = 1–4) (SD) 1.80 (0.57) 1.78 (0.54) 1.83 (0.60)b
aNo significant difference between groups: t(1029) = −0.149, p = 0.882
bNo significant difference between groups: t(1029) = −1.336, p = 0.182
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ascertain whether this affects informed decision mak-
ing outcomes.
Conclusion
This study found that a web-based decision aid about
(genetic) risk-stratified ovarian cancer screening signifi-
cantly increased women’s knowledge about ovarian can-
cer. No differences in knowledge or other components
of informed decision-making between participants who
viewed a gist version vs. an extended version of the deci-
sion aid were observed. Further research is needed to
determine the ideal volume and type of content for deci-
sion aids about stratified ovarian cancer risk-
management.
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